Processing your payment...
Please do not close your browser.

CD38 Monoclonal Antibody Drugs Market- Global Growth, Trends and Forecast (2022 - 2029) By Type (Daratumumab, Isatuximab) By Application (Pharmacy, Laboratory Use), and By Regions

28 Jun, 2022 | 92 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Over the forecast period, the CD38 Monoclonal Antibody Drugs Market will register a CAGR of 14.1 % in terms of revenue and the global market size will reach USD 155 Billion by 2029.

CD38 Monoclonal Antibody Drugs Market Overview

Monoclonal bodies have demonstrated promising benefits in immunotherapy. Since these monoclonal bodies were created by the artificial development of a cell clone, they only contain one kind of immunoglobulin. These are employed as targets because they can bind to antigens and create complex structures. Monoclonal antibodies against the CD38 surface antigen of hematopoietic cells are being produced. Through the destruction of CD38 activities, which results in cell death, this binding mechanism slows the development of the tumor.

Due to factors including the increased frequency of the target illnesses and the rising need for monoclonal antibodies, the market for CD38 monoclonal antibodies is predicted to expand rapidly in the upcoming years. It is anticipated that the adverse impacts and production challenges would restrain market expansion. During the anticipated period, the market for CD38 monoclonal antibodies is anticipated to expand rapidly. The research analyses important trends and opportunities in the market and delivers vital information on the competitive landscape for the main manufacturers of CD38 monoclonal antibodies.

What is our CD38 Monoclonal Antibody Drugs Market report scope?

 

Report Attributes

 

 

Report Details

 

Forecast Period 2022 to 2029

 

CAGR of 14.1 % during the review period (2022 to 2029).

 

By Type

  • Daratumumab
  • Isatuximab

 

By Application

 

 

 

 

  • Pharmacy
  • Laboratory Use

 

 

 

By Companies

  • Johnson and Johnson
  • Sanofi
  • Janssen Biotech
  • Carbosynth
  • Creative Biolabs
  • BOC Sciences
  • CASI Pharmaceuticals Inc.
  • Kleo Pharmaceuticals
  • Kiadis Pharma N.V.
  • Fate Therapeutics

 

 

 

Regions Covered

 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

 

 

 

 

 

 

 

Countries Covered

  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America

 

Historical Year

 

 

2017 to 2021

Forecast Year

 

2022 to 2029

Number of Pages

92

 

Customization Available

 

 

Yes, the report can be customized as per your needs

Who are the Major Players in CD38 Monoclonal Antibody Drugs Market?

Market Growth Reports lists out all the CD38 Monoclonal Antibody Drugs Market companies that are presently striving to reduce the impact of the Covid-19 pandemic on the Market- Johnson and Johnson, Sanofi, Janssen Biotech, Carbosynth, Creative Biolabs, BOC Sciences, CASI Pharmaceuticals Inc., Kleo Pharmaceuticals, Kiadis Pharma N.V., Fate Therapeutics, Others

Industry News:

Sanofi: FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

PARIS – March 2, 2020 – The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Sarclisa is expected to be available to patients in the U.S. shortly.

What are the major Type, Products, and End Users for CD38 Monoclonal Antibody Drugs Market?

By Type, it is segmented into

  • Vaccines
  • Veterinary Drugs

By Application, it is segmented into

  • Pharmacy
  • Laboratory Use

By End User, it is segmented into

  • Hospitals
  • Laboratories
  • Veterinary Clinics

CD38 Monoclonal Antibody Drugs Market Regional Analysis

The market in the area is characterized by rising illness prevalence and need for treatment, together with rising disease diagnosis and adoption of cutting-edge therapies. The area has a significant share of the worldwide market due to these reasons, as well as the patient population's increased healthcare expenditures toward novel treatment alternatives and the presence of major businesses with their pipeline candidates and planned releases. During the projection period, it is anticipated that the markets in Europe and the Asia Pacific would account for a sizeable portion of the market.

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East & Africa
    • Latin America
  1. INTRODUCTION
    • MARKET DEFINITION
    • MARKET DYNAMICS
    • MARKET SEGMENTATION
    • REPORT TIMELINES
    • KEY STAKEHOLDERS
  2. RESEARCH METHODOLOGY
    • DATA MINING
      • SECONDARY RESEARCH
      • PRIMARY RESEARCH
      • SUBJECT MATTER EXPERT ADVICE
    • QUALITY CHECK
    • FINAL REVIEW
      • DATA TRIANGULATION
      • BOTTOM-UP APPROACH
      • TOP-DOWN APPROACH
      • RESEARCH FLOW
  3. EXECUTIVE SUMMARY
    • INTRODUCTION
    • GLOBAL CD38 MONOCLONAL ANTIBODY DRUGS MARKET BY TYPES
    • GLOBAL CD38 MONOCLONAL ANTIBODY DRUGS MARKET BY APPLICATION
  4. MARKET DYNAMICS
    • DRIVERS
      • INCREASING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASE
    • RESTRAINTS
      • STRINGENT ENVIRONMENTAL REGULATIONS
      • HIGH COST OF MATERIALS
    • OPPORTUNITIES
      • CD38 MONOCLONAL ANTIBODY DRUGS GROWTH
    • APPLICATION OF CD38 MONOCLONAL ANTIBODY DRUGS IMPACT ON COVID 19
  5. GLOBAL CD38 MONOCLONAL ANTIBODY DRUGS MARKET, BY TYPES
    • INTRODUCTION
    • DARATUMUMAB
    • ISATUXIMAB
  6. GLOBAL CD38 MONOCLONAL ANTIBODY DRUGS MARKET, BY APPLICATION
    • INTRODUCTION
    • PHARMACY
    • LABORATORY USE
  7. GLOBAL CD38 MONOCLONAL ANTIBODY DRUGS MARKET, BY REGION
    • NORTH AMERICA
      • US
      • CANADA
      • MEXICO
    • EUROPE
      • GERMANY
      • FRANCE
      • UK
      • ITALY
      • RUSSIA
      • REST OF EUROPE
    • APAC
      • CHINA
      • SOUTH KOREA
      • JAPAN
      • INDIA
      • AUSTRALIA
      • ASEAN
      • REST OF APAC
    • MIDDLE EAST AND AFRICA
      • SAUDI ARABIA
      • UAE
      • SOUTH AFRICA
      • TURKEY
      • REST OF MEA
    • SOUTH AMERICA
      • BRAZIL
      • REST OF MEA
      • ARGENTINA
      • REST OF SOUTH AMERICA
  8. COMPETITIVE LANDSCAPE
    • MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
    • AND AGREEMENTS
      • KEY DEVELOPMENT
    • MARKET SHARE PERCENT/RANKING ANALYSIS
    • STRATEGIES ADOPTED BY LEADING PLAYERS
  9. COMPANY PROFILES
    • BUSINESS OVERVIEW
    • COMPANY SNAPSHOT
    • PRODUCT BENCHMARKING
    • STRATEGIC INITIATIVES
  1. JOHNSON AND JOHNSON
  2. SANOFI
  3. JANSSEN BIOTECH
  4. CARBOSYNTH
  5. CREATIVE BIOLABS
  6. BOC SCIENCES
  7. CASI PHARMACEUTICALS INC.
  8. KLEO PHARMACEUTICALS
  9. KIADIS PHARMA N.V.
  10. FATE THERAPEUTICS

 

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Request A Sample

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • Korean Institute of Tuberculosis
  • Sanyo chemical Industries LTD
  • Novartis
  • Hisamitsu
  • Pfizer
  • AbbVie
  • RevHealth
  • Zeon Corporation
  • Abbott (Established Pharmaceutical Products)
  • Sinopharm (pharmaceutical distribution segment)
  • Takeda Pharmaceutical
  • Gilead Sciences
  • Sartorius
  • Zavation
  • Permobil
  • Ansell
  • Cefla